ArticleInvestigational new drugs2020

Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.

Xing Hao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.